Achieve Life Sciences highlights cytisinicline path to FDA approval, commercial launch in corporate presentation

Reuters2026/09/02 21:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Achieve Life Sciences investor presentation outlined plans to push smoking-cessation drug cytisinicline toward US approval, with a PDUFA date of Jun 20, 2026.
Phase 3 pooled data showed continuous abstinence of 31.5% vs 8.2% on placebo at weeks 9-12; odds ratio 5.3.
At weeks 9-24, pooled continuous abstinence was 20.8% vs 4.5%; odds ratio 5.5.
Financing package totals up to $354 million, including $180 million upfront and up to $174 million in FDA-approval-triggered warrants.
Commercial buildout highlighted hires from Verona Pharma’s Ohtuvayre launch team, positioning for a potential US launch in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Achieve Life Sciences highlights cytisinicline path to FDA approval, commercial launch in corporate presentation

You may also like

Crypto prices